Inovalon Holdings Inc(NASDAQ:INOV) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Feb 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $96.093M. Analysts estimated a revenue of $95.100M. The revenues were 1.04% above the estimates. Earnings per share were $0.05. The reported EPS was above estimates by 66.67%. Analysts had estimated an EPS of $0.03.
In a different note, On Dec 20, 2016, KeyBanc said it Downgrades its rating on Inovalon Holdings Inc. The shares have been rated ‘Sector Weight’ by the firm. On Dec 13, 2016, Wells Fargo said it Downgrades its rating on Inovalon Holdings Inc. The shares have been rated ‘Market Perform’ by the firm.
Inovalon Holdings Inc (INOV) shares turned negative on Wednesdays trading session with the shares closing down -0.5 points or -4.27% at a volume of 6,00,147. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $11.65. The peak price level was also seen at $11.65 while the days lowest was $11.1. Finally the shares closed at $11.2. The 52-week high of the shares is $20.05 while the 52-week low is $8.6. According to the latest information available, the market cap of the company is $1,647 M.
Several Insider Transactions has been reported to the SEC. On Dec 19, 2016, Robert A Wychulis (President) purchased 1,675 shares at $9.29 per share price.Also, On Dec 19, 2016, Andre S Hoffmann (director 10% owner) purchased 200,000 shares at $9.29 per share price.On Dec 16, 2016, William D Green (director) purchased 30,000 shares at $9.29 per share price, according to the Form-4 filing with the securities and exchange commission.
Inovalon Holdings Inc. is a technology company. The Company combines advanced cloud-based data analytics and data-driven intervention platforms to provide services for health plans hospitals physicians patients pharmaceutical companies and researchers. Through its datasets integration technologies predictive analytics and subject matter expertise the Company delivers platforms. Its analytics identify gaps in care quality data integrity and financial performance while providing clients with capabilities to resolve these gaps. The Company’s data analytics and intervention platforms consist of four primary components: data integration advanced analytics intervention platforms and business processing. This system manages the process of defining and configuring industry data feeds from its clients and partners including electronic health records laboratory pharmacy patient reported claims paper based medical records biometric and hospital data feeds.